McAlister VC, Haddad E, Renouf E et al (2006) Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 6:1578–1585. https://doi.org/10.1111/j.1600-6143.2006.01360.x
Article CAS PubMed Google Scholar
Haddad E, McAlister V, Renouf E et al (2006) Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006:CD005161. https://doi.org/10.1002/14651858.CD005161.pub2
Article PubMed PubMed Central Google Scholar
Jain A, Mazariegos G, Pokharna R et al (2003) The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis1. Transplantation 75:1020–1025. https://doi.org/10.1097/01.TP.0000056168.79903.20
Article CAS PubMed Google Scholar
Venkataramanan R, Swaminathan A, Prasad T et al (1995) Clinical pharmacokinetics of tacrolimus: Clin Pharmacokinet 29:404–430. https://doi.org/10.2165/00003088-199529060-00003
Article CAS PubMed Google Scholar
Sanchez MJ, Manzanares C, Santos-Buelga D et al (2001) Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 40:63–71. https://doi.org/10.2165/00003088-200140010-00005
Ji E, Kim MG, Oh JM (2018) CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag 14:2119–2126. https://doi.org/10.2147/TCRM.S184376
Article CAS PubMed PubMed Central Google Scholar
Zhu L, Yang J, Zhang Y et al (2015) Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Xenobiotica 45:840–846. https://doi.org/10.3109/00498254.2015.1021733
Article CAS PubMed Google Scholar
Guy-Viterbo V, Baudet H, Elens L et al (2014) Influence of donor–recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics 15:1207–1221. https://doi.org/10.2217/pgs.14.75
Article CAS PubMed Google Scholar
Yang J, Liao S, Zhu L et al (2015) Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther 53:75–83. https://doi.org/10.5414/CP202189
Article CAS PubMed Google Scholar
Musuamba FT, Guy-Viterbo V, Reding R et al (2014) Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. Ther Drug Monit 36:54–61. https://doi.org/10.1097/FTD.0b013e31829dcbcd
Article CAS PubMed Google Scholar
Guy-Viterbo V, Scohy A, Verbeeck RK et al (2013) Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol 69:1533–1542. https://doi.org/10.1007/s00228-013-1501-0
Article CAS PubMed Google Scholar
Abdel Jalil MH, Hawwa AF, McKiernan PJ et al (2014) Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Brit J Clin Pharmacol 77:130–140. https://doi.org/10.1111/bcp.12174
Fukudo M, Yano I, Masuda S et al (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80:331–345. https://doi.org/10.1016/j.clpt.2006.06.008
Article CAS PubMed Google Scholar
Chen B, Shi HQ, Liu XX et al (2017) Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther 42:679–688. https://doi.org/10.1111/jcpt.12599
Article CAS PubMed Google Scholar
Fukatsu S, Yano I, Igarashi T et al (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57:479–484. https://doi.org/10.1007/s002280100331
Article CAS PubMed Google Scholar
Wallin JE, Bergstrand M, Wilczek HE et al (2011) Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit 33:663–672. https://doi.org/10.1097/FTD.0b013e31823415cc
Article CAS PubMed Google Scholar
Zhu L, Wang H, Sun X et al (2014) The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients. J Pharm (Cairo) 2014:713650. https://doi.org/10.1155/2014/713650
Kassir N, Labbé L, Delaloye J-R et al (2014) Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients: tacrolimus in paediatric liver transplant recipients. Brit J Clin Pharmacol 77:1051–1063. https://doi.org/10.1111/bcp.12276
Chen X, Wang DD, Xu H, Li ZP (2020) Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation. Transl Pediatr 9:576–586. https://doi.org/10.21037/tp-20-84
Article PubMed PubMed Central Google Scholar
Sam WJ, Tham LS, Holmes MJ et al (2006) Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet 45:59–75. https://doi.org/10.2165/00003088-200645010-00004
Article CAS PubMed Google Scholar
Zahir H, McLachlan AJ, Nelson A et al (2005) Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 27:422–430. https://doi.org/10.1097/01.ftd.0000170029.36573.a0
Article CAS PubMed Google Scholar
Lu Y, Su Q, Wu K et al (2015) A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin 36:281–288. https://doi.org/10.1038/aps.2014.110
Article CAS PubMed Google Scholar
Staatz CE, Taylor PJ, Lynch SV et al (2001) Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 72:1056–1061. https://doi.org/10.1097/00007890-200109270-00013
Article CAS PubMed Google Scholar
Li D, Lu W, Zhu J-Y et al (2007) Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients: tacrolimus population pharmacokinetics and CYP3A5. J Clin Pharm Ther 32:505–515. https://doi.org/10.1111/j.1365-2710.2007.00850.x
Article CAS PubMed Google Scholar
Sam WJ, Aw M, Quak SH et al (2000) Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Brit J Clin Pharmacol 50:531–541. https://doi.org/10.1046/j.1365-2125.2000.00288.x
Khamlek K, Komenkul V, Sriboonruang T, Wattanavijitkul T (2024) Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: a systematic review. Brit J Clin Pharmacol 90:406–426. https://doi.org/10.1111/bcp.15909
Shao J, Wang C, Fu P et al (2020) Impact of donor and recipient CYP3A5*3 genotype on tacrolimus population pharmacokinetics in Chinese adult liver transplant recipients. Ann Pharmacother 54:652–661. https://doi.org/10.1177/1060028019897050
Article CAS PubMed Google Scholar
Moes DJAR, Van Der Bent SAS, Swen JJ et al (2016) Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol 72:163–174. https://doi.org/10.1007/s00228-015-1963-3
Comments (0)